Fiche publication
Date publication
août 2024
Journal
Bulletin du cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BINQUET Christine
,
Pr LEJEUNE Catherine
,
Pr LEPAGE Côme
,
Dr MEUNIER-BEILLARD Nicolas
Tous les auteurs :
El Chami C, Meunier-Beillard N, Binquet C, Lepage C, Lejeune C
Lien Pubmed
Résumé
The better understanding of the molecular, cellular, and immunological mechanisms of cancer has led to the development of targeted therapies, then immunotherapy, which have changed the approach to cancer treatment. While these treatments differ from chemotherapy in their mechanisms of action, they also allow for increased personalization of cancer care through the development of technologies that target patients more precisely. However, they are associated with several challenges: the management of uncertainty associated with their risk-benefit balance due to the lack of long-term data and sometimes scientific evidence on their effects; the complexity of integrating molecular and immunological data into the therapeutic decision; the challenge of inequalities in access to these treatments often considered revolutionary due to the required molecular characterization and/or inclusion criteria for early-phase trials; and the challenge of their appropriation and adoption by physicians and patients. This narrative review explores each of these challenges in the context of shared decision-making, the promotion of which is a guarantee of quality and safety of care for cancer patients.
Mots clés
Balance bénéfice–risque, Benefit–risk balance, Cancer, Immunotherapy, Immunothérapie, Incertitude, Innovation, Targeted therapies, Thérapies ciblées, Uncertainty
Référence
Bull Cancer. 2024 08 28;:
